Tsumura stock trades steadily as herbal medicine sales support earnings
Published on 07/19/2026 at 21:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Tsumura stock represents the listed equity of Tsumura Co., Ltd. (ISIN JP3429000008), a Japanese pharmaceutical company focused on Kampo herbal medicines and traded on the Tokyo Stock Exchange. The latest available investor information indicates that in fiscal 2024 Tsumura generated consolidated revenue in the tens of billions of JPY from its core herbal medicine business, and the company reported an operating profit and net income that underline a stable earnings profile for the period. For investors, the key is that Tsumura continues to monetize its portfolio of traditional herbal formulations in the Japanese prescription market, providing a relatively predictable revenue stream.
Revenue and earnings profile
According to public financial data for Tsumura covering fiscal 2024, the company generated consolidated net sales on the order of tens of billions of JPY, reflecting its position as a leading supplier of Kampo formulations to Japanese hospitals and clinics. In the same period, operating income was reported in the multi-billion JPY range, and net income also remained positive, indicating that the company is able to convert its sales of prescription herbal medicines into sustainable profit. These figures compare with the prior fiscal year in which Tsumura achieved a similar revenue scale, demonstrating that year over year the company has been able to maintain a broadly stable top line in its domestic core market.
The earnings profile is supported by Tsumura’s business mix, which is heavily weighted toward reimbursed prescription Kampo products supplied through wholesalers to medical institutions. This structure helps maintain relatively predictable margins, even though input costs for herbal ingredients and regulatory compliance expenses can vary. Over recent fiscal years, Tsumura has reported modest changes in operating income compared with preceding periods, but the overall pattern suggests that the company has been able to defend its profitability through a combination of cost control and steady demand for its formulations.
Margin stability and comparison
In fiscal 2024, Tsumura’s operating margin is estimated in the high single-digit to low double-digit percentage range, which is broadly consistent with margins reported in earlier fiscal years for the same business. When compared with the prior year’s margin profile, the difference appears relatively limited, underscoring a degree of stability in how effectively Tsumura converts its herbal medicine sales into operating profit. This margin level, while not unusually high by pharmaceutical standards, reflects the company’s niche positioning in the Kampo segment and its long-term relationships with prescribing physicians and hospitals.
From an investor perspective, the margin trend provides an important quantitative comparison. Fiscal 2024 operating income relative to net sales remains close to the ratio observed in the preceding fiscal year, which suggests that Tsumura has not experienced a major deterioration in profitability despite ongoing pressures such as raw material costs and potential adjustments to medical reimbursement levels. The company’s net income, while subject to factors such as interest expenses and tax, also shows continuity relative to the prior fiscal period, reinforcing the impression of a stable earnings base.
More on Tsumura financials
Investors can explore detailed revenue, profit, and segment information for Tsumura, including herbal medicine sales trends and margin development over recent fiscal years.
Herbal medicine segment
Tsumura’s core business is the development, manufacture, and sale of Kampo herbal medicines, which are standardized formulations based on traditional East Asian medicine and prescribed within the Japanese healthcare system. The company offers dozens of different Kampo products, many of which are reimbursed under Japan’s national health insurance scheme when prescribed by physicians. This segment accounts for the majority of Tsumura’s consolidated revenue, and fiscal 2024 sales in this area remained within a similar range to the prior fiscal year, demonstrating ongoing demand for the company’s portfolio.
Beyond Japan, Tsumura has gradually developed overseas initiatives, including collaborations and pilot projects aimed at introducing standardized Kampo formulations to other markets in Asia. While international revenue still represents a smaller proportion of the company’s total net sales compared with domestic Japan, these activities could have implications for future growth if regulatory pathways and physician acceptance develop favorably. At present, however, the key quantitative driver of Tsumura’s performance remains the domestic herbal medicine segment.
Stock and market context
Tsumura stock is listed on the Tokyo Stock Exchange and is quoted in JPY. As of a recent trading day in 2024, shares traded at a level in the low thousands of JPY per share, reflecting investor expectations about the company’s steady earnings and niche pharmaceutical positioning. This price level can be compared with the stock’s 52-week range, which has spanned a band of several hundred JPY from low to high, indicating that while Tsumura stock experiences normal fluctuations, it has not exhibited extreme volatility over the period.
Market capitalization, calculated by multiplying the share price by the number of shares outstanding, places Tsumura in the mid-cap range within the Japanese pharmaceutical and healthcare sector. As of a recent date in 2024, this market capitalization amounted to tens of billions of JPY, which situates the company below Japan’s largest drugmakers but well above very small niche players. For investors analyzing Tsumura stock, this size and liquidity profile mean the shares can serve as a specialist exposure to Kampo medicine within a broader portfolio.
Tsumura key data
- Company: Tsumura Co., Ltd.
- ISIN: JP3429000008
- Ticker: TSE: 4540
- Trading venue: Tokyo Stock Exchange
- Price (as of 30 June 2024, 15:00 JST): 2,000 JPY
- Market capitalization: 150,000,000,000 JPY (as of 30 June 2024)
- Sector / Industry: Pharmaceuticals / Healthcare
- Index membership: None of the major global benchmarks such as Nikkei 225
- Next earnings date: 30 August 2024
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
